The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation.
Adolescent
Adoptive Transfer
/ methods
Child
Child, Preschool
Encephalitis
/ immunology
Female
Graft vs Host Disease
/ immunology
Hematopoietic Stem Cell Transplantation
/ methods
Herpesvirus 6, Human
/ immunology
Humans
Infant
Killer Cells, Natural
/ immunology
Lymphocyte Depletion
Male
Roseolovirus Infections
/ immunology
T-Lymphocytes
/ immunology
Transplantation, Homologous
/ methods
encephalitis
haploidentical stem cell transplantation
human herpesvirus-6
natural killer cells
Journal
Transfusion
ISSN: 1537-2995
Titre abrégé: Transfusion
Pays: United States
ID NLM: 0417360
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
16
01
2021
received:
25
11
2020
accepted:
17
01
2021
pubmed:
14
3
2021
medline:
27
7
2021
entrez:
13
3
2021
Statut:
ppublish
Résumé
Naïve T-cell-depleted grafts have been employed as an ex vivo T-cell depletion (TCD) platform to prevent graft-versus-host disease (GvHD) and improve immune reconstitution by providing rapid donor memory T-cell reconstitution after allogenic hematopoietic stem cell transplantation (allo-HSCT). CD45RA We report the first 18 consecutive allo-HSCT, 16 haplo-HSCT, and two human leukocyte antigen-matched related donors implanted with naïve TCD grafts. All donors were administered three cell products: first, a CD34 Engraftment was achieved in 94.5% of cases; 2-year overall survival, event-free survival, and GvHD/relapse-free survival were 87.2% (95% CI 78.6-95.8), 67.3% (95% CI 53.1-81.5), and 64% (95% CI 50.5-78.1), respectively. HHV-6B reactivation occurred in 7 of the haplo-HSCT patients, six of who received a cell infusion with an NK/CD4 ratio <2. None of the patients developed encephalitis. In this clinical study, we show that early adoptive NK cell infusion after a 45RA
Sections du résumé
BACKGROUND
Naïve T-cell-depleted grafts have been employed as an ex vivo T-cell depletion (TCD) platform to prevent graft-versus-host disease (GvHD) and improve immune reconstitution by providing rapid donor memory T-cell reconstitution after allogenic hematopoietic stem cell transplantation (allo-HSCT). CD45RA
METHODS
We report the first 18 consecutive allo-HSCT, 16 haplo-HSCT, and two human leukocyte antigen-matched related donors implanted with naïve TCD grafts. All donors were administered three cell products: first, a CD34
RESULTS
Engraftment was achieved in 94.5% of cases; 2-year overall survival, event-free survival, and GvHD/relapse-free survival were 87.2% (95% CI 78.6-95.8), 67.3% (95% CI 53.1-81.5), and 64% (95% CI 50.5-78.1), respectively. HHV-6B reactivation occurred in 7 of the haplo-HSCT patients, six of who received a cell infusion with an NK/CD4 ratio <2. None of the patients developed encephalitis.
CONCLUSIONS
In this clinical study, we show that early adoptive NK cell infusion after a 45RA
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1505-1517Subventions
Organisme : CRIS Cancer Foundation
Organisme : Instituto de Salud Carlos III (ISCIII)
ID : FONDOS FEDER grant (FIS) PI18/01301
Informations de copyright
© 2021 AABB.
Références
Locatelli F, Merli P, Pagliara D, Li Pira G, Falco M, Pende D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSCT after αβ T-cell and B-cell depletion. Blood. 2017;130(5):677-85. https://doi.org/10.1182/blood-2017-04-779769.
Mamcarz E, Madden R, Qudeimat A, Srinivasan A, Talleur A, Sharma A, et al. Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution. Bone Marrow Transplant. 2020;55(5):929-38. https://doi.org/10.1038/s41409-019-0750-7.
Düver F, Weißbrich B, Eyrich M, Wölfl M, Schlegel PG, Wiegering V. Viral reactivations following hematopoietic stem cell transplantation in pediatric patients - A single center 11-year analysis. PLoS One. 2020;15(2):e0228451. https://doi.org/10.1371/journal.pone.0228451.
Crocchiolo R, Bramanti S, Vai A, Sarina B, Mineri R, Casari E, et al. Infections after T-replete haploidentical transplantation and high-dose cyclophosphamide as graft-versus-host disease prophylaxis. Transpl Infect Dis. 2015;17(2):242-9. https://doi.org/10.1111/tid.12365.
Gokgoz Z, Arslan O. Haploidentical stem cell transplantation: T cell depleted and repleted. Transfus Apher Sci. 2018;57(2):171-3. https://doi.org/10.1016/j.transci.2018.04.016.
Atay D, Akcay A, Erbey F, Ozturk G. The impact of alternative donor types on viral infections in pediatric hematopoietic stem cell transplantation. Pediatr Transplant. 2018;22(2):e13109. https://doi.org/10.1111/petr.13109.
Or-Geva N, Reisner Y. The evolution of T-cell depletion in haploidentical stem-cell transplantation. Br J Haematol. 2016;172(5):667-84. https://doi.org/10.1111/bjh.13868.
Vadakekolathu J, Rutella S. T-cell manipulation strategies to prevent graft-versus-host disease in haploidentical stem cell transplantation. Biomedicines. 2017;5(2):33. https://doi.org/10.3390/biomedicines5020033.
Li Pira G, Di Cecca S, Montanari M, Moretta L, Manca F. Specific removal of alloreactive T-cells to prevent GvHD in hemopoietic stem cell transplantation: Rationale, strategies and perspectives. Blood Rev. 2016;30(4):297-307. https://doi.org/10.1016/j.blre.2016.03.001.
Bleakley M, Heimfeld S, Loeb KR, Jones LA, Chaney C, Seropian S, et al. Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts. J Clin Invest. 2015;125(7):2677-89. https://doi.org/10.1172/JCI81229.
Bleakley M, Heimfeld S, Jones LA, Turtle C, Krause D, Riddell SR, et al. Engineering human peripheral blood stem cell grafts that are depleted of naïve T cells and retain functional pathogen-specific memory T cells. Biol Blood Marrow Transplant. 2014;20(5):705-16. https://doi.org/10.1016/j.bbmt.2014.01.032.
Shook DR, Triplett BM, Eldridge PW, Kang G, Srinivasan A, Leung W. Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability. Pediatr Blood Cancer. 2015;62(4):666-73. https://doi.org/10.1002/pbc.25352.
Triplett BM, Shook DR, Eldridge P, Li Y, Kang G, Dallas M, et al. Rapid memory T-cell reconstitution recapitulating CD45RA-depleted haploidentical transplant graft content in patients with hematologic malignancies [published correction appears in Bone Marrow Transplant. 2015 Jul;50(7):1012]. Bone Marrow Transplant. 2015;50(7):968-77. https://doi.org/10.1038/bmt.2014.324.
Triplett BM, Muller B, Kang G, Li Y, Cross SJ, Moen J, et al. Selective T-cell depletion targeting CD45RA reduces viremia and enhances early T-cell recovery compared with CD3-targeted T-cell depletion. Transpl Infect Dis. 2018;20(1): 1-17. https://doi.org/10.1111/tid.12823.
Sisinni L, Gasior M, de Paz R, Querol S, Bueno D, Fernández L, et al. Unexpected high incidence of human herpesvirus-6 encephalitis after naive T cell-depleted graft of haploidentical stem cell transplantation in pediatric patients. Biol Blood Marrow Transplant. 2018;24(11):2316-23. https://doi.org/10.1016/j.bbmt.2018.07.016.
Perruccio K, Sisinni L, Perez-Martinez A, Valentin J, Capolsini I, Massei MS, et al. High incidence of early human herpesvirus-6 infection in children undergoing haploidentical manipulated stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2018;24(12):2549-57. https://doi.org/10.1016/j.bbmt.2018.07.033.
Shachor-Meyouhas Y, Fesenko A, Kra-Oz Z, Zaidman I, Szwarcwort-Cohen M, Shafran E, et al. Human herpes virus-6 following pediatric allogeneic hematopoietic stem cell transplantation. Isr Med Assoc J. 2015;17(5):302-5.
Winestone LE, Punn R, Tamaresis JS, Buckingham J, Pinsky BA, Waggoner JJ, et al. High human herpesvirus 6 viral load in pediatric allogeneic hematopoietic stem cell transplant patients is associated with detection in end organs and high mortality. Pediatr Transplant. 2018;22(2):1-18. https://doi.org/10.1111/petr.13084.
Olson AL, Dahi PB, Zheng J, Devlin SM, Lubin M, Gonzales AM, et al. Frequent human herpesvirus-6 viremia but low incidence of encephalitis in double-unit cord blood recipients transplanted without antithymocyte globulin. Biol Blood Marrow Transplant. 2014;20(6):787-93. https://doi.org/10.1016/j.bbmt.2014.02.010.
Ogata M, Oshima K, Ikebe T, Takano K, Kanamori H, Kondo T, et al. Clinical characteristics and outcome of human herpesvirus-6 encephalitis after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(11):1563-70. https://doi.org/10.1038/bmt.2017.175.
Ogata M, Fukuda T, Teshima T. Human herpesvirus-6 encephalitis after allogeneic hematopoietic cell transplantation: What we do and do not know. Bone Marrow Transplant. 2015;50(8):1030-6. https://doi.org/10.1038/bmt.2015.76.
Hanson DJ, Hill JA, Koelle DM. Advances in the characterization of the T-cell response to human herpesvirus-6. Front Immunol. 2018;9:1454. https://doi.org/10.3389/fimmu.2018.01454.
Sakai R, Kanamori H, Motohashi K, Yamamoto W, Matsuura S, Fujita A, et al. Long-term outcome of human herpesvirus-6 encephalitis after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17(9):1389-94. https://doi.org/10.1016/j.bbmt.2011.01.014.
Fida M, Hamdi AM, Bryson A, Razonable RR, Abu Saleh O. Long-term outcomes of patients with human herpesvirus 6 encephalitis. Open Forum Infect Dis. 2019;6(7):ofz269. https://doi.org/10.1093/ofid/ofz269.
Miyashita N, Endo T, Onozawa M, Hashimoto D, Kondo T, Fujimoto K, et al. Risk factors of human herpesvirus 6 encephalitis/myelitis after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis. 2017;19(3):1-10. https://doi.org/10.1111/tid.12682.
Ward KN, Hill JA, Hubacek P, de la Camara R, Crocchiolo R, Einsele H, et al. Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation. Haematologica. 2019;104(11):2155-63. https://doi.org/10.3324/haematol.2019.223073.
Greco R, Crucitti L, Noviello M, Racca S, Mannina D, Forcina A, et al. Human herpesvirus 6 infection following haploidentical transplantation: Immune recovery and outcome. Biol Blood Marrow Transplant. 2016;22(12):2250-5. https://doi.org/10.1016/j.bbmt.2016.09.018.
Tzannou I, Papadopoulou A, Naik S, Leung K, Martinez CA, Ramos CA, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation. J Clin Oncol. 2017;35(31):3547-57. https://doi.org/10.1200/JCO.2017.73.0655.
Eliassen E, Di Luca D, Rizzo R, Barao I. The interplay between natural killer cells and human herpesvirus-6. Viruses. 2017;9(12):367. https://doi.org/10.3390/v9120367.
Hammer Q, Rückert T, Romagnani C. Natural killer cell specificity for viral infections. Nat Immunol. 2018;19(8):800-8. https://doi.org/10.1038/s41590-018-0163-6.
Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461-9. https://doi.org/10.1182/blood-2007-09-077438.
De Pelsmaeker S, Romero N, Vitale M, Favoreel HW. Herpesvirus evasion of natural killer cells. J Virol. 2018;92(11):e02105-17. https://doi.org/10.1128/JVI.02105-17.
Della Chiesa M, De Maria A, Muccio L, Bozzano F, Sivori S, Moretta L. Human NK cells and herpesviruses: Mechanisms of recognition, response and adaptation. Front Microbiol. 2019;10:2297. https://doi.org/10.3389/fmicb.2019.02297.
Diaz MA, Pérez-Martínez A, Herrero B, Deltoro N, Martinez I, Ramirez M, et al. Prognostic factors and outcomes for pediatric patients receiving an haploidentical relative allogeneic transplant using CD3/CD19-depleted grafts. Bone Marrow Transplant. 2016;51(9):1211-6. https://doi.org/10.1038/bmt.2016.101.
Ocanto A, Escribano A, Glaría L, Rodríguez I, Ferrer C, Huertas C, et al. TLI in pediatric patients. Clin Transl Oncol. 2020;22(6):884-91. https://doi.org/10.1007/s12094-019-02205-9.
Koehl U, Brehm C, Huenecke S, Kloess S, Bremm M, Zimmermann SY, et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol. 2013;3:118. https://doi.org/10.3389/fonc.2013.00118.
Fernández L, Leivas A, Valentín J, Escudero A, Corral D, de Paz R, et al. How do we manufacture clinical-grade interleukin-15-stimulated natural killer cell products for cancer treatment? Transfusion. 2018;58(6):1340-7. https://doi.org/10.1111/trf.14573.
Harris AC, Young R, Devine S, Hogan WJ, Ayuk F, Bunworasate U, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: A report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2016;22(1):4-10.
Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D, Cowen EW, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015;21(3):389-401.e1.
Tuttolomondo A, Colomba C, Di Bona D, Casuccio A, Di Bona D, Aiello A, et al. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute viral encephalitis. Oncotarget. 2018;9(25):17523-32. https://doi.org/10.18632/oncotarget.24778.
Della Chiesa M, Falco M, Podestà M, Locatelli F, Moretta L, Frassoni F, et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: A role for human cytomegalovirus? Blood. 2012;119(2):399-410. https://doi.org/10.1182/blood-2011-08-372003.
Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012;119(11):2665-74. https://doi.org/10.1182/blood-2011-10-386995.
Muccio L, Bertaina A, Falco M, Pende D, Meazza R, Lopez-Botet M, et al. Analysis of memory-like natural killer cells in human cytomegalovirus-infected children undergoing αβ+T and B cell-depleted hematopoietic stem cell transplantation for hematological malignancies. Haematologica. 2016;101(3):371-81. https://doi.org/10.3324/haematol.2015.134155.
Iesato K, Hori T, Yoto Y, Yamamoto M, Inazawa N, Kamo K, et al. Long-term prognosis of human herpesvirus 6 reactivation following allogeneic hematopoietic stem cell transplantation. Pediatr Int. 2018;60(6):547-52. https://doi.org/10.1111/ped.13551.
Marabelle A, Bergeron C, Billaud G, Mekki Y, Girard S. Hemophagocytic syndrome revealing primary HHV-6 infection. J Pediatr. 2010;157(3):511. https://doi.org/10.1016/j.jpeds.2010.02.064.
Pérez-Martínez A, Ferreras C, Pascual A, Gonzalez-Vicent M, Alonso L, Badell I, et al. Haploidentical transplantation in high-risk pediatric leukemia: A retrospective comparative analysis on behalf of the Spanish working group for bone marrow transplantation in children (GETMON) and the Spanish Grupo for hematopoietic transplantation (GETH). Am J Hematol. 2020;95(1):28-37. https://doi.org/10.1002/ajh.25661.
Kim DH, Sohn SK, Won DI, Lee NY, Suh JS, Lee KB. Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant. 2006;37(12):1119-28. https://doi.org/10.1038/sj.bmt.1705381.